Results 31 to 40 of about 2,036 (191)

Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study [PDF]

Italian Journal of Pediatrics
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in pediatric populations, resulting in a substantial burden of disease.
Elisa Funiciello, Alessia Spadavecchia, Celeste Cagnazzo, Lorenza Ferrara, Bartolomeo Griglio, Antonino Sottile, Paola Berchialla, Franca Fagioli, on behalf of the Piemonitorab Study Group   +8 more
doaj   +2 more sources

The Impact of Nirsevimab on the Transport of Critically Ill Children. [PDF]

Children (Basel)
Purpose: Respiratory syncytial virus-positive bronchiolitis continues to be the main diagnosis prompting transportation in children younger than one year of age. It represents approximately 15–20% of all services performed by a specialized pediatric transport team.
Alejandre C, Pazos E, Gonzalez-Alvarez P, Girona-Alarcón M, Millán N, Rodriguez M, Covas A, Martinez Planas A, Esteban E.   +8 more
europepmc   +4 more sources

Parental Acceptance of Nirsevimab for RSV Prevention in Infants Across Two Consecutive Seasons in Emilia-Romagna, Italy

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab, a long-acting monoclonal antibody, provides single-dose protection during the RSV season, but the ...
Susanna Esposito, Valentina Fainardi, Maria Elena Capra, Melodie O. Aricò, Angela Lanzoni, Francesco Accomando, Gaia Giorgia Arnesano, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci, Serafina Perrone   +10 more
doaj   +2 more sources

Potential Effects on Elderly People From Nirsevimab Use in Infants

Open Respiratory Archives
Nirsevimab therapy has the potential to revolutionize infant respiratory syncytial virus (RSV) prophylaxis. But other populations suffering RSV, such the elderly or those over 60, may also be protected by using this novel antibody in the infant group. It
JOSÉ M Eirós, Ivan Sanz-Muñoz
exaly   +3 more sources

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France

The Lancet Microbe
Summary: Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants. Nirsevimab, a long-acting monoclonal antibody targeting a conserved epitope on the prefusion F protein (site Φ), has shown high ...
ProfPhD Slim Fourati, Alawiya Reslan, PhD, Jérôme Bourret, PhD, Jean-Sébastien Casalegno, PhD, Yannis Rahou, Laurent Softic, PhD, Lionel Chollet, MD, Pauline Trémeaux, PhD, ProfPhD Berthe-Marie Imbert-Marcille, PhD, Sylvie Pillet, PhD, Nicolas Veyrenche, PhD, Agathe Boudet, PhD, Luc Deroche, MD, ProfPhD Sonia Burrel, MD, Lina Mouna, PharmD, Theophile Cocherie, MD, Aurélie Schnuriger, PhD, Charlotte Pronier, PhD, Lynda Handala, PharmD, Véronique Brodard, PhD, Floriane Gallais, PhD, Sylvie Larrat, PhD, Alexandre Regueme, PharmD, Nefert Candace Dossou, PharmD, Amandine Henry, PharmD, ProfPhD Elyanne Gault, PharmD, Cédric Hartard, PhD, Ségolène Brichler, PhD, Alice Moisan, PhD, ProfPhD Véronique Avettand-Fenoel, PhD, Caroline Lefeuvre, PharmD, Ilka Engelmann, PhD, ProfPhD Sandrine Castelain, PhD, Audrey Mirand, PhD, Maud Salmona, PhD, Marie-Christine Jaffar-Bandjee, PhD, Mohamed Ader, Sarah Seng, Pierre Cappy, PhD, ProfPhD Christophe Rodriguez, PhD, Arnaud Ly, Georges Dos Santos, PhD, ProfPhD Olivier Schwartz, PhD, Chloé Petiot, Delphine Planas, PhD, Samar Berreira Ibraim, PhD, Kévin Da Silva, PhD, Amélie Recoing, MD, ProfPhD Jean-Michel Pawlotsky, MD, Frédéric Lemoine, PhD, ProfPhD Etienne Audureau, PhD, ProfPhD Marie-Anne Rameix-Welti, PhD, Naël Zemali, Sonia Burrel, Pantxika Bellecave, Alice Moisan, Zakasoa-Mbololona Zavaoarisaina, Romain Legros, Boris Derman, Vincent Pargny, Hortense Petat, Jean-Christophe Plantier, Véronique Avettand-Fenoel, Salim Ferrani, Jérome Guinard, Clémence Guillaume, Gilbert Mchantaf, Victoria Marie, Laurent Bret, Fabien Lesne, Anthony de Oliveira, Alexandre Regueme, Kazali Alidjinou, Lionel Chollet, Vincent Gardan, Ségolène Brichler, Loic de Pontual, Camille Aupiais, Stéphane Marot, Aurélie Schnuriger, Marine Perrier, Pierre Jatteau, Djeneba Fofana, Théophile Cocherie, Elisa Teyssou, Cathia Soulié, Vincent Calvez, Sylvie Larrat, Anne Faisant, Guillaume Mortamet, Caroline Tournegros, Mohamed Habib, Sylvie Pillet, Aymeric Cantais, Franck Zekre, Thomas Bourlet, Oulfa Boussetta-Charfi, Sara Chenafi-Adham, Eva Gleizes, Cédric Hartard, Caroline Lefeuvre, Elise Bouthry, Lina Mouna, Fairly Warnakulasuriya, Quentin Le Hingrat, Marie-Christine Jaffar-Bandjee, Diana Heaugwane, Benjamin Azemar, Nicolas Mnemosyme, Laurent Souply, Catherine François, Sandrine Castelain, Cinthia Rames, Arnaud Bécourt, Ilka Engelmann, Eric Jeziorski, Vincent Foulongne, Lynda Handala, Catherine Gaudy-Graffin, Agathe Crémadés, Amandine Henry, Alessandra Pennisi, Maud Salmona, Jérôme Le Goff, Audrey Gabassi, Marie-Laure Néré, Marine Minier, Audrey Baron, Stéphane Bonacorsi, Naim Ouldali, Abdeljalil Senhaji Rachik, Marie-Anne Rameix-Welti, Alawyia Reslan, Yannis Rahou, Banujaa Jeyarajah, Anne Huard de Verneuil, Jérome Bourret, Frédéric Lemoine, Kévin Da Silva, Samar Berreira Ibraim, Vincent Enouf, Danielle Perez-Bercoff, Lucy Mosscrop, Etienne Simon-Loriere, Nefert Candace Dossou, Astrid Vabret, Slim Fourati, Christophe Rodriguez, Jean-Michel Pawlotsky, Pierre Cappy, Alexandre Soulier, Mohamed Ader, Sarah Seng, Arnaud Ly, Amandine Caillault, Pierre-André Natella, Etienne Audureau, Georges Dos Santos, Laurence Fagour, Anne-Julie Schapira, Olivier Flechelles, Luc Deroche, Nicolas Lévêque, Claire Morton Fauche, Sarah Borel, Erwan Ripley, Juliette Aubin, Berthe-Marie Imbert, Louise Castain, Audreay Rodallec, Justine Sourice, Christele Gras-Le Guen, Anne Chauvire-Drouard, Elyanne Gault, Frédérique Moreau, Claire Deback, Floriane Gallais, Morgane Solis, Valentin Stephan, Léa Pilorgé, Sophie Vallet, Léa Gaitan, Sylvie Rogez, Audrey Mirand, Cecile Henquell, Charlotte Pronier, Claire Grolhier, Vincent Thibault, Pauline Trémeaux, Isabelle Claudet, Mélanie Pucelle, Laetitia Staes, Camille Vellas, Sofia Demmou, Romain Carcenac, Nicolas Veyrenche, Jean-sébastien Casalegno, Alexandre Gaymard, Jose Kombou, Antonin Bal, Stanislas Ogoudjobi, Agathe Boudet, Amélie Recoing   +202 more
doaj   +2 more sources

Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross-Sectional Study. [PDF]

Pediatr Pulmonol
ABSTRACT Introduction New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers.
Rose A, Datta RR, Di Chiara C, Piché-Renaud PP, Morris SK.   +4 more
europepmc   +2 more sources

Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case–control study, Spain, October 2023 to March 2025 [PDF]

Eurosurveillance
BACKGROUND In autumn 2023, Spain recommended nirsevimab to all infants born after 1 April 2023, as catch-up or at-birth immunisation. AIM We estimated effectiveness of a single nirsevimab dose against respiratory syncytial virus (RSV) hospitalisations ...
the Nirsevimab Effectiveness Study Collaborators
doaj   +2 more sources

Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study. [PDF]

Pediatr Pulmonol
Introduction: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants. In 2024, the monoclonal antibody nirsevimab became available in Italy for all newborns during their first RSV season. Aims: The
La Regina DP, Spatuzzo M, Bonci E, Nenna R, Petrarca L, Conti MG, Mancino E, Pierangeli A, Antonelli G, Midulla F.   +9 more
europepmc   +2 more sources

Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants. [PDF]

Pediatr Pulmonol
ABSTRACT Introduction Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024.
Tarizzo M, Mesinèle J, Prevost B, Denamur S, Peulier-Maitre E, Guillot L, Nathan N, Corvol H.   +7 more
europepmc   +2 more sources

Evaluation of nirsevimab against rsv infection in infants

, 2023
19 p.ill.,LIST OF TABLES 1 -- BACKGROUND 3 -- 1 BACKGROUND 4 -- 2 METHODS 4 -- 3 CLINICAL EVIDENCE 7 -- 3.1 NIRSEVIMAB IN PRETERM INFANTS 7 -- 3.2 NIRSEVIMAB IN LATE-PRETERM AND TERM INFANTS 9 -- 3.3 MEDLEY TRIAL 14 -- 3.4 HARMONIE TRIAL (PRELIMINARY ...
Desimpel, Fabian
core   +1 more source